Freenome Inc. (FRNM:NASDAQ) closed at $10.77 on November 10, 2026, up 1.89% on the day. The stock trades 38.5% below its 52-week high of $17.50 and 10.9% above its 52-week low of $9.71. Over the past year, it lost 25.6%. Freenome Inc. is part of the Health Care sector.
In 200 trading sessions since January 27, 2026, FRNM closed higher on 85 days (43%). Its best day was August 17, 2026 (+12.46%) and its worst was October 12, 2026 (-16.22%). The stock moved 10% or more in a single session 5 times.
Freenome is an early cancer detection company developing blood-based screening tests to identify cancer in its earliest, most treatable stages. The company's proprietary multiomics discovery platform analyzes circulating cell-free DNA methylation patterns at single-base resolution alongside additional biomarkers to detect multiple cancers. Freenome's development of SimpleScreen¿ CRC for colorectal cancer screening, with clinical validation through the PREEMPT CRC Study, and a pipeline of tests for lung cancer and additional indications is designed to increase cancer screening participation among millions of at-risk individuals.
Find more stocks like FRNM with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.